BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sino Biopharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sino Biopharmaceutical's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06202261-9077@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Culmerciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study of TQB2930 for Injection Monotherapy or Combination Therap
 y in Patients With Recurrent/Metastatic Breast Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06202261
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-9077@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Culmerciclib\, phase 3.\nStudy: Clinical Study on Adjuvant Ther
 apy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combi
 ned With Endocrine Therapy in Patients With Breast Cancer\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464587-1558@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:TQC3721: Phase 3 readout est. (NCT07464587)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate
 -to-Severe Chronic Obstructive Pulmonary Disease\nEstimated primary comple
 tion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tqc3721#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07464587
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-1558@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TQC3721: Phase 3 readout est. (NCT07147946)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Pati
 ents With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tqc3721#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07147946
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406035-52@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:TQH3906: Phase 2 readout est. (NCT07406035)
DESCRIPTION:TQH3906\, phase 2\, Psoriatic Arthritis.\nStudy: A Clinical Tri
 al of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07406035
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724366-52@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:TQH3906: Phase 3 readout est. (NCT07724366)
DESCRIPTION:TQH3906\, phase 3\, Psoriasis.\nStudy: A Clinical Trial of TQH3
 906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07724366
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509892-52@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TQH3906: Phase 2 readout est. (NCT07509892)
DESCRIPTION:TQH3906\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Cli
 nical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Syst
 emic Lupus Erythematosus\nEstimated primary completion: November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tqh3906#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07509892
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379946-2488@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 1/2 readout est. (NCT05379946)
DESCRIPTION:Anfangning (Garsorasib)\, phase 1/2.\nStudy: Study to Evaluate 
 D-1553 in Combination With IN10018 in Subjects With Solid Tumors\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05379946
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393321-9073@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:NTQ1062: Phase 3 readout est. (NCT07393321)
DESCRIPTION:NTQ1062\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for
  the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ntq1062#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07393321
URL:https://assetmemo.bio/drug/ntq1062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-9845@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:TQA3605: Phase 3 readout est. (NCT07797231)
DESCRIPTION:TQA3605\, phase 3\, Chronic Hepatitis B.\nStudy: Clinical Trial
  of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus
  NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus In
 fection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Re
 sponse\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tqa3605#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/tqa3605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569757-3389@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TQB2934: Phase 3 readout est. (NCT07569757)
DESCRIPTION:TQB2934\, phase 3\, Multiple Myeloma.\nStudy: Clinical Study of
  TQB2934 Injection in Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tqb2934#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07569757
URL:https://assetmemo.bio/drug/tqb2934#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
